- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne Schmidt Discusses Reimbursing for Telemedicine
Until there is more data to support the outcomes of using telemedicine, payers will be more cautious about getting into reimbursing for the technology, said Anne Schmidt, MD, associate medical director at Blue Cross and Blue Shield of Alabama.
Until there is more data to support the outcomes of using telemedicine, payers will be more cautious about getting into reimbursing for the technology, said Anne Schmidt, MD, associate medical director at Blue Cross and Blue Shield of Alabama.
Transcript (slightly modified)
Why has there seemed to be a reluctance to dive into reimbursing telemedicine?
As far as reimbursement for telemedicine, I think that as payers we're all looking for new ways to optimize health outcomes. So I'm not sure that I'd say "reluctance" to dive into telemedicine—as payers, again, we are more conservative than some other groups that are out there. And we realize that the better outcomes that we can promote for our members—physicians, patients—the better off we all will be: financially, patients will have better outcomes; physicians will have better satisfaction—job satisfaction—and better outcomes for themselves.
So I think what we're looking for is more evidence right now. More data to just support the fact that there are better outcomes, and I think Medicare's NDPP [National Diabetes Prevention Program] and the fact that they are now going to reimburse for that gives us some data to support that.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
